Paris – 12 October 2012 – NYSE Euronext (NYX) today announced the listing on NYSE Alternext in Paris of Novacyt, a specialist in next-generation cytology solutions.
Novacyt lists on NYSE Alternext
Founded in 2006, Novacyt designs, develops and markets innovative liquid-based cytology solutions with applications in molecular biology. The company’s NovaPrep® Processor System uses fully patented technology to optimise detection of precancerous and cancerous lesions. Novacyt is present in France and on international markets through a network of 13 distributors. Its products carry the EC-IVD label in Europe and the SFDA label in China, and it has received a marketing authorisation for Russia.
Novacyt (ticker: ALNOV) was listed through admission to trading of 2,389,335 existing shares and 318,127 new shares issuedunder a Global Offering. The Global Offering raised a total of €2.6 million, with theadmission and issue price of shares set at €8.10 per share. Market capitalisation stood at around €22 million on the day of listing.
“We are delighted to welcome Novacyt to NYSE Alternext, where listing will enable it to pursue development of new products to help detect cancers in a variety of countries,” said Marc Lefèvre, Head of European Business Development and Client Coverage at NYSE Euronext. “Backed by our trading platform and very wide network of members, NYSE Alternext – our market designed especially for small and mid-size companies – offers both listed companies and investors access to a unique pool of liquidity.”
Eric Peltier, Chairman and CEO of Novacyt added: “We would like to thank all our shareholders for their trust, which has enabled us to take this major step. They will now be able to accompany us as our R&D programmes develop new products to round out our existing range and improve cancer detection and diagnostics.”
In seven years, €2.7 billion has been raised on NYSE Alternext, half through secondary issues, by companies from Belgium, Canada, China, France, Italy, Luxembourg, the Netherlands, Spain, the UK and the US. Their market capitalisation totals €6 billion. Today 183 companies are listed on NYSE Alternext.
Caroline Tourrier: +33 (0)1 49 27 10 82
Karen Beberac: +33 (0)1 53 70 29 42
Sophie Boulila / Emmanuel Huynh: +33 (0)1 44 71 94 91
Emilie Dèbes / Caroline Carmagnol: +33 (0)1 42 68 86 40
About NYSE Euronext
NYSE Euronext (NYX) is a leading global operator of financial markets and provider of innovative trading technologies. The company's exchanges in Europe and the United States trade equities, futures, options, fixed-income and exchange-traded products. With approximately 8,000 listed issues (excluding European Structured Products), NYSE Euronext's equities markets — the New York Stock Exchange, NYSE Euronext, NYSE MKT, NYSE Alternext and NYSE Arca — represent one-third of the world’s equities trading, the most liquidity of any global exchange group. NYSE Euronext also operates NYSE Liffe, one of Europe’s leading derivatives businesses and the world's second-largest derivatives business by value of trading. The company offers a comprehensive range of technology, connectivity and market data products and services through NYSE Technologies. NYSE Euronext is included in the S&P 500 index. For more information, visit: http://www.nyx.com.
Novacyt was founded in 2006 to design, develop and market innovative liquid-based cytology solutions with applications in molecular biology. Recognised by OSEO as an “innovative business”, Novacyt took less than five years to develop and market its NovaPrep® Processor System, the most highly automated and most secure modular cytology solution used today. Backed by fully patented technology, this system opens new horizons in cytology, both for mass screening and individual diagnosis. This next-generation cytology offers the best in cytological sampling to optimise detection of precancerous and cancerous lesions. Novacyt is present in France and on international markets through a network of 13 distributors; it has been authorised to use the EC-IVD label in Europe since 2008, and, more recently, the SFDA label in China, and the company has also been granted a marketing authorisation for Russia. Since Novacyt’s first products went on the market in 2008, they have been used for over 1,000,000 tests reimbursed by healthcare authorities. For more information, visit: www.novacyt.com.
The Global Offering was made up of an Open Price Public Offering and a Global Placement with institutional investors in France and other countries.